Spesolimab: First Approval

Spesolimab (spesolimab-sbzo; SPEVIGO(®)) is an interleukin (IL)-36 receptor antagonist being developed by Boehringer Ingelheim for the treatment of various immune-mediated disorders. In September 2022, spesolimab was approved in the USA for the treatment of generalized pustular psoriasis (GPP) flare...

Descripción completa

Detalles Bibliográficos
Autor principal: Blair, Hannah A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
AdisInsight Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9744699/
https://www.ncbi.nlm.nih.gov/pubmed/36418672
http://dx.doi.org/10.1007/s40265-022-01801-4
Descripción
Sumario:Spesolimab (spesolimab-sbzo; SPEVIGO(®)) is an interleukin (IL)-36 receptor antagonist being developed by Boehringer Ingelheim for the treatment of various immune-mediated disorders. In September 2022, spesolimab was approved in the USA for the treatment of generalized pustular psoriasis (GPP) flares in adults. This article summarizes the milestones in the development of spesolimab leading to this first approval for GPP flares. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40265-022-01801-4.

Ejemplares similares